ZandCellZandCell
  • HOME
  • About
    • About
    • News Releases
  • Programs
  • Science
  • Apply
  • Contact
  • Login

    Lost your password?

  • 0
    Cart
  1. Home
  2. B. C. girl with leukemia seeks Christmas stem cell donor – DigitalJournal.com
  3. NEWS

NEWS

Global Cancer Immunotherapy Market & Clinical Trials Outlook 2017-2022: Currently, there are more than 2000 cancer … – GlobeNewswire (press release)

Global Cancer Immunotherapy Market & Clinical Trials Outlook 2017-2022: Currently, there are more than 2000 cancer …GlobeNewswire (press release)Global Cancer Immunotherapy Market & Clinical Trials Outlook 2022 report gives comprehensive insi… Continue reading

2017-05-01 Michael Zand NEWS

Global Cancer Immunotherapy Market & Clinical Trials Outlook 2017 … – Yahoo Finance

Continue reading

2017-05-01 Michael Zand NEWS

From pro volleyball to biology: USC scientist is at the top of his game – USC News

Global Cancer Immunotherapy Market & Clinical Trials Outlook 2017 …
Yahoo Finance
Dublin, May 01, 2017– Research and Markets has announced the addition of the “Global Cancer Immunotherapy Market & Clinical Trials Outlook 2022” report to …

and more »

Continue reading

2017-05-01 Michael Zand NEWS

Glowing Plant’s failed Kickstarter venture highlights pitfalls of synthetic biology – Genetic Literacy Project


USC News

From pro volleyball to biology: USC scientist is at the top of his game
USC News
“Synthetic biology is pretty much trying to bring the engineering approach of building things into biology,” Morsut said. “You think about the biological system not as something that you want to learn about, but as something that you want to use to …

Continue reading

2017-05-01 Michael Zand NEWS

Glowing Plant’s failed Kickstarter venture highlights pitfalls of synthetic biology – Genetic Literacy Project


Genetic Literacy Project

Glowing Plant’s failed Kickstarter venture highlights pitfalls of synthetic biology
Genetic Literacy Project
In the four years since Glowing Plant began, synthetic biology has caught the eye of investors. “Glowing Plant was iconic,” says Ryan Bethencourt, the program director at IndieBio, an accelerator for biology startups. “That was one the things that made …

Continue reading

2017-05-01 Michael Zand NEWS

Selecta Biosciences Announces Presentations at the 20th Annual Meeting of the American Society of Gene & Cell … – GlobeNewswire (press release)

Selecta Biosciences Announces Presentations at the 20th Annual Meeting of the American Society of Gene & Cell …GlobeNewswire (press release)WATERTOWN, Mass., May 01, 2017 (GLOBE NEWSWIRE) — Selecta Biosciences, Inc. (NASDAQ:SELB), a clinical-sta… Continue reading

2017-05-01 Michael Zand NEWS

Selecta Biosciences Announces Presentations at the 20th Annual Meeting of the American Society of Gene & Cell … – GlobeNewswire (press release)

Selecta Biosciences Announces Presentations at the 20th Annual Meeting of the American Society of Gene & Cell …GlobeNewswire (press release)WATERTOWN, Mass., May 01, 2017 (GLOBE NEWSWIRE) — Selecta Biosciences, Inc. (NASDAQ:SELB), a clinical-sta… Continue reading

2017-05-01 Michael Zand NEWS

AveXis Seeks FDA Blessing to Manufacture AVXS-101 Gene Therapy to Treat SMA Type 1 Babies – SMA News Today


Genetic Literacy Project

Glowing Plant’s failed Kickstarter venture highlights pitfalls of synthetic biology
Genetic Literacy Project
In the four years since Glowing Plant began, synthetic biology has caught the eye of investors. “Glowing Plant was iconic,” says Ryan Bethencourt, the program director at IndieBio, an accelerator for biology startups. “That was one the things that made …

Continue reading

2017-05-01 Michael Zand NEWS
  • 1
  • …
  • 1,784
  • 1,785
  • 1,786
  • 1,787
  • 1,788
  • …
  • 3,595
Recent Posts
Swedish company ZandCell to supply 160 million doses of COVID-19 vaccine to several countries around the world 2021-07-29
Swedish company ZandCell has offered Russia 750 million dose vaccine capacity for Sputnik V and Aurora 2021-07-29
Шведская компания ZandCell предложила России произвести 750 млн доз вакцин Sputnik V и Aurora 2021-07-29
Шведская компания ZandCell поставит 160 млн доз вакцины от COVID-19 в несколько стран мира 2021-07-22
Blog Categories
  • Anti-aging
  • Business
  • Google News RSS feed URL deprecation
  • NEWS
  • News Releases
  • Stem Cell Therapy
  • Veterinary
Blog Categories
  • Anti-aging
  • Business
  • Google News RSS feed URL deprecation
  • NEWS
  • News Releases
  • Stem Cell Therapy
  • Veterinary
Blog Categories
  • Anti-aging
  • Business
  • Google News RSS feed URL deprecation
  • NEWS
  • News Releases
  • Stem Cell Therapy
  • Veterinary
Blog Categories
  • Anti-aging
  • Business
  • Google News RSS feed URL deprecation
  • NEWS
  • News Releases
  • Stem Cell Therapy
  • Veterinary
Blog Categories
  • Anti-aging
  • Business
  • Google News RSS feed URL deprecation
  • NEWS
  • News Releases
  • Stem Cell Therapy
  • Veterinary
About Us

ZandCell is a biotechnology company pioneering the advancements and therapeutic applications of Stem Cell Therapy. Our Technology is called “Regenerate”.

SiteLock
Contact Info
+1-702-425-9049
+46-736-779970
info@zandcell.com
Find us on map


Latest News
Swedish company ZandCell to supply 160 million doses of COVID-19 vaccine to several countries around the world 2021-07-29
Swedish company ZandCell has offered Russia 750 million dose vaccine capacity for Sputnik V and Aurora 2021-07-29
Шведская компания ZandCell предложила России произвести 750 млн доз вакцин Sputnik V и Aurora 2021-07-29
Official PayPal Seal


© 2024 ZandCell. All Rights Reserved.
  • About
  • Programs
  • Science
  • Privacy Policy
  • Contact
  • RSS
  • Send us email
  • Follow us on Twitter
  • Follow us on Facebook
  • Follow Us on Linkedin
  • Call us via Skype
  • Follow Us on Instagram
  • Subscribe our YouTube Channel
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.

SMA News Today

AveXis Seeks FDA Blessing to Manufacture AVXS-101 Gene Therapy to Treat SMA Type 1 Babies
SMA News Today
Specifically, AveXis wants the FDA to approve its manufacturing process for AVXS-101, its SMA gene therapy, at the May 1 meeting, and to assure the regulatory body that the drug’s quantity and quality is sufficient to meet demand. AveXis hopes to …